"Lopinavir/ritonavir (Kaletra) taken once-daily as part of a combination antiretroviral regimen worked as well as the approved twice-daily dose in previously treated patients but led to better adherence, researchers reported on Tuesday at the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Cape Town, South Africa.
"Past studies have shown that once-daily and twice-daily Kaletra work equally well in people starting treatment for the first time. Study M06-802 was designed to see whether this was also the case for treatment-experienced patients. There had been previous concerns that once-daily Kaletra might be less effective in treatment-experienced patients."
Read more in Aidsmap, July 24, 2009.
0 comments:
Post a Comment